VaxInnate Inc.
This article was originally published in Start Up
Executive Summary
VaxInnate is linking the innate and adaptive immune response to get the optimal action from a vaccine. Work done in the Yale labs of company founders demonstrated that fusing a polypeptide ligand specific for a TLR to an antigen of interest generates a vaccine that may prove more potent and selective than the antigen alone. It also eliminates the need for formulating the vaccine in complex adjuvants-and it opens the door to production using simplified recombinant methods.
You may also be interested in...
Can Diseases of Poverty Pay?
Medicines to fight significant global health problems are scarce because the lack of commercial return trumps the fact that drug targets are well characterized and the required R&D investment is relatively inexpensive. The Gates Foundation hopes to create a more robust marketplace for global health medicines through non-dilutive funding. Gates money, plus Priority Review Vouchers and other creative tactics to ensure a market for these medicines may also persuade companies to develop drugs for long overlooked diseases such as malaria and tuberculosis. It's not yet clear whether these alternate funding schemes will prove attractive, but they may start making global health increasingly a part of business planning.
NasVax Ltd.
NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family of positively charged polycationic lipids. The technology generates strong adjuvant activity, with the potential for intranasal, intramuscular, or subcutaneous administration. This platform can also be applied to boost the bioactivity of various immunomodulators, such as a broad spectrum of well-established adjuvants and cytokines.
FluGen Inc.
FluGen aims to improve vaccine manufacturing and ultimately create better, safer, flu vaccines as well as treatments for the viral infections. The start-up is not basing its business model on the possibility of any sort of worldwide pandemic--but its founders' expertise with such matters brings credibility that is bound to be useful in attracting potential partners.